Paronychia Treatment Market Size, Share, Trends, Dynamics and Competitive Analysis

The Paronychia Treatment Market size is estimated at USD 631.05 Million in 2024 and is expected to reach USD 1150.84 Million by 2032, at a CAGR of 7.8% during the forecast period (2025-2032).

Format : PDF | Report ID : SMR_2825

Paronychia Treatment Market Overview:

The Paronychia Treatment Market, a widespread nail infection, is gradually expanding with an increase in bacterial, fungal, and viral nail infections. The expansion is of very high importance among diabetics or individuals working in water-exposure occupations. International giant pharmaceutical firms such as Pfizer, GlaxoSmithKline (GSK), and Novartis, and over-the-counter pharmaceutical firms such as Johnson & Johnson and Bayer are the market leaders in this market. The leader in the market today is North America, yet the Asia-Pacific market is a high-growth market with enhanced healthcare access and rising disposable incomes.

Drivers for growth are greater awareness, enhanced access, and growing demand for non-surgical procedures. Resistance to drugs and potential side effects are the industry's challenge. It is increasingly competitive with the consolidation of companies, the development of new medicines, and innovation, such as Bausch Health's innovation in research on antifungal drugs. Drivers for the market are affordable drugs available on the market, the use of AI in dermatology, and penetration in under-penetrated markets.

The market for paronychia treatment is reassuring with revenue development anticipated in terms of prescription and over-the-counter medication. The market is prompted by novel formulations of drugs, synergy among the players in the industry, and improved healthcare facilities. Overall, the market is anticipated to record spectacular growth within the next couple of years.

Paronychia Treatment Snapshot

To get more Insights: Request Free Sample Report

Paronychia Treatment Market Dynamics:

Advancements in Topical and Systemic Therapeutics to Boost the Paronychia Treatment Market

Emerging topical and systemic therapies have effectively altered the treatment paradigm for paronychia. Modern antifungal creams, ointments and oral antibiotics are designed to specifically target pathogens as well, thus minimizing the duration of treatment and improving patient outcomes. These developments address both acute and chronic cases. Trends in drug delivery systems, including sustained-release systems and bioactive coatings, are further augmenting the effectiveness of these therapies. Analysis highlights the significance of these innovations in overcoming patient compliance problems and reducing recurrence rates and thus making them the foundation of contemporary paronychia treatment.

Potential Side Effects of Prolonged Medication to Restrain Paronychia Treatment Market

Although topical and systemic treatments are successful, long-term use of antifungals and antibiotics has been shown to cause side effects, such as skin irritation, gastrointestinal upset, and the development of antibiotic-resistant organisms. Such side effects can deter patients from following their prescribed regimens, especially in conditions that need to be treated long term. Healthcare trends stress the need to weigh efficacy against safety. SMR analysis, indicates that the creation of targeted and less invasive treatments will be essential to overcoming these impediments and enhancing patient compliance with treatment regimens.

Paronychia Treatment Market Regional Analysis:

Market analysis of paronychia treatment finds, it is driven by enormous population, higher cases of fungal infections and enhanced healthcare facilities in China, India, and Japan. China is shown through analysis to be leading the region with rising need for antifungal therapy with a high rate of skin and nail diseases. India's expanding healthcare sector permits the application of prescription and over-the-counter medication for acute and chronic paronychia. Japan emphasizes advanced and new therapies with the best use of its powerful pharmaceutical sector in treating nail diseases. Affordability issues and poor access to sophisticated treatment in rural regions can be a spoilsport in some regions, though.

Paronychia Treatment Market Segment Analysis:

Based on Type, the market is segmented into chronic paronychia and acute paronychia. Acute paronychia accounted for the highest revenue in paronychia treatment market share in 2024. Acute paronychia is a common condition caused by bacterial infection and typically requires immediate treatment. Availability of strong antibiotics and topical medications to cure acute ones has enabled the segment to lead. Increased recognition of the importance of early medical management of acute infections has stimulated demand for this category.

Based on Treatment, the market is segmented into medications and surgery. The medications segment held the highest paronychia treatment market share revenue in 2024. Antibiotics, antifungals, topical medications and anti-inflammatories are the bare minimum line of treatment for paronychia. The presence of pre-prepared topical and oral medication for acute and chronic disease has driven surge. Growing awareness of self-management of mild illness through over-the-counter drugs has fuelled segment growth. Technological advancements in drugs, including rapid-acting topical creams, are enhancing treatment effectiveness and patient compliance.

Paronychia Treatment by treatment

Based on End-User, Hospitals segment generated the largest revenue share in 2024. Hospitals are key sources of full care for paronychia because they possess more diagnosis and therapy procedures. Multidisciplinary personnel and specialist operating units available in hospitals ensure effective management of serious cases. Higher hospitalization of advanced or chronic paronychia is promoting hospital-based treatments. Higher investment in hospitals and dermatology units is driving the segment growth.

Paronychia Treatment Market Competitive Landscape:

The Paronychia Treatment Market has different important players including GlaxoSmithKline, Glenmark Generics, Teva Pharmaceutical Industries, Eli Lilly, Jonakayem Pharma Formulation, Fougera Pharmaceuticals, and Taro Pharmaceutical Industries. They are engaged in developing treatment for this common nail infection with increasing cases and developing demand for effective treatments.

GlaxoSmithKline is a strong competitor with an active portfolio in dermatology. With research and development focusing on enhancing treatment efficacy, it aims to achieve a vast market share through innovative solutions. The company earned high revenue from its pharmaceutical business, which helped it achieve its growth trajectory. Teva Pharmaceutical Industries, another major player, has advanced in the business of generic drugs, offering cheaper alternatives for Paronychia treatment. They are motivated by a diversification drive in their generic portfolio. Eli Lilly, being prominent with molecular innovation is also in the dermatology treatments field. As it is not specifically engaged to be entirely working in Paronychia only, its overall experience is poised well to develop more in similar avenues. Moreover, Taro Pharmaceutical Industries has emerged as a player in the field of topical treatment. Its dermatology orientation positions it well to expand its product line.

Together, these players are expected to have strong growth in the Paronychia treatment market, as the awareness and incidence of nail infections increase. The size of the overall market is expected to grow with the increased demand for quality treatment, leaving enough scope for these players to innovate and command a larger share in the market.

Paronychia Treatment Market Scope
Market Size in 2024	USD 631.05 Million
Market Size in 2032	USD 1150.84 Million
CAGR (2025-2032)	7.8%
Historic Data	2019-2024
Base Year	2024
Forecast Period	2025-2032
Segments	By Type Acute Paronychia Chronic Paronychia
	By Treatment Medications Surgical Interventions
	By End-User Hospitals Dermatology Clinics Ambulatory Surgical Centres
Regional Scope	North America- United States, Canada, and Mexico Europe – UK, France, Germany, Italy, Spain, Sweden, Russia, and Rest of Europe Asia Pacific – China, South Korea, Japan, India, Australia, Indonesia, Philippines, Malaysia, Vietnam, Thailand, Rest of APAC Middle East and Africa - South Africa, GCC, Egypt, Nigeria, Rest of the Middle East and Africa South America – Brazil, Argentina, Rest of South America

Key players in the Paronychia Treatment Market:

Pfizer Inc. (New York, USA)
Novartis AG (Basel, Switzerland)
GlaxoSmithKline plc (GSK) (London, UK)
Johnson & Johnson (New Brunswick, USA)
Merck & Co., Inc. (Kenilworth, USA)
AbbVie Inc. (North Chicago, USA)
Bayer AG (Leverkusen, Germany)
Sanofi S.A. (Paris, France)
Roche Holding AG (Basel, Switzerland)
AstraZeneca plc (Cambridge, UK)
Bristol-Myers Squibb Company (New York, USA)
Eli Lilly and Company (Indianapolis, USA)
Amgen Inc. (Thousand Oaks, USA)
Teva Pharmaceutical Industries Ltd. (Tel Aviv, Israel)
Mylan N.V. (Canonsburg, USA)
Sun Pharmaceutical Industries Ltd. (Mumbai, India)
Lupin Limited (Mumbai, India)
Dr. Reddy’s Laboratories Ltd. (Hyderabad, India)
Cipla Limited (Mumbai, India)
Hikma Pharmaceuticals PLC (London, UK)
3M Company (Saint Paul, USA)
Smith & Nephew plc (London, UK)
Medtronic plc (Dublin, Ireland)
Becton, Dickinson and Company (Franklin Lakes, USA)
Stryker Corporation (Kalamazoo, USA)
ConvaTec Group plc (Reading, UK)
Mölnlycke Health Care AB (Gothenburg, Sweden)
Coloplast A/S (Humlebaek, Denmark)
Mayo Clinic (Rochester, USA)
Cleveland Clinic (Cleveland, USA

Buy Now

Request For Free sample

Frequently Asked Questions

Who are the key players in the Paronychia Treatment Market?

Various Pharmaceutical companies (Pfizer Inc., Novartis AG, GlaxoSmithKline), Medical device companies (3M Company, Smith & Nephew, Medtronic) and Healthcare providers (Mayo Clinic, Cleveland Clinic) are driving the market.

What are the market segments in the Paronychia Treatment Market?

The market segments in the Paronychia Treatment Market are By type, By Treatment and By End-User.

Which type of Paronychia has the largest market share?

Acute Paronychia has the largest market share in the year 2024.

Which region is leading the Paronychia Treatment Market?

Asia Pacific region is leading the Paronychia Treatment Market

What are the challenges in the Paronychia Treatment Market?

Side effects caused due to prolonged use of the medications related to the Paronychia Treatment is the biggest challenge in the Paronychia Treatment Market.

1. Paronychia Treatment Market Introduction
1.1. Study Assumption and Market Definition
1.2. Scope of the Study
1.3. Executive Summary

2. Global Paronychia Treatment Market: Competitive Landscape
2.1. Ecosystem Analysis
2.2. SMR Competition Matrix
2.3. Competitive Landscape
2.4. Key Players Benchmarking
2.4.1. Company Name
2.4.2. Business Segment
2.4.3. End-user Segment
2.4.4. Revenue (2024)
2.4.5. Company Locations
2.5. Market Structure
2.5.1. Market Leaders
2.5.2. Market Followers
2.5.3. Emerging Players
2.6. Mergers and Acquisitions Details

3. Paronychia Treatment Market: Dynamics
3.1. Paronychia Treatment Market Trends by Region
3.1.1. North America Paronychia Treatment Market Trends
3.1.2. Europe Paronychia Treatment Market Trends
3.1.3. Asia Pacific Paronychia Treatment Market Trends
3.1.4. Middle East and Africa Paronychia Treatment Market Trends
3.1.5. South America Paronychia Treatment Market Trends
3.2. Paronychia Treatment Market Dynamics
3.2.1. Paronychia Treatment Market Drivers
3.2.2. Paronychia Treatment Market Restraints
3.2.3. Paronychia Treatment Market Opportunities
3.2.4. Paronychia Treatment Market Challenges
3.3. PORTER’s Five Forces Analysis
3.4. PESTLE Analysis
3.5. Regulatory Landscape by Region
3.5.1. North America
3.5.2. Europe
3.5.3. Asia Pacific
3.5.4. Middle East and Africa
3.5.5. South America
3.6. Key Opinion Leader Analysis for Paronychia Treatment Industry

4. Paronychia Treatment Market: Global Market Size and Forecast by Segmentation (by Value in USD Million) (2024-2032)
4.1. Paronychia Treatment Market Size and Forecast, By Type (2024-2032)
4.1.1. Acute Paronychia
4.1.2. Chronic Paronychia
4.2. Paronychia Treatment Market Size and Forecast, By Treatment (2024-2032)
4.2.1. Medications
4.2.2. Surgical Interventions
4.3. Paronychia Treatment Market Size and Forecast, By End User (2024-2032)
4.3.1. Hospitals
4.3.2. Dermatology Clinics
4.3.3. Ambulatory Surgical Centres
4.4. Paronychia Treatment Market Size and Forecast, by Region (2024-2032)
4.4.1. North America
4.4.2. Europe
4.4.3. Asia Pacific
4.4.4. Middle East and Africa
4.4.5. South America

5. North America Paronychia Treatment Market Size and Forecast by Segmentation (by Value in USD Million) (2024-2032)
5.1. North America Paronychia Treatment Market Size and Forecast, By Type (2024-2032)
5.1.1. Acute Paronychia
5.1.2. Chronic Paronychia
5.2. North America Paronychia Treatment Market Size and Forecast, By Treatment (2024-2032)
5.2.1. Medications
5.2.2. Surgical Interventions
5.3. North America Paronychia Treatment Market Size and Forecast, By End User (2024-2032)
5.3.1. Hospitals
5.3.2. Dermatology Clinics
5.3.3. Ambulatory Surgical Centres
5.4. North America Paronychia Treatment Market Size and Forecast, by Country (2024-2032)
5.4.1. United States
5.4.1.1. United States Paronychia Treatment Market Size and Forecast, By Type (2024-2032)
5.4.1.1.1. Acute Paronychia
5.4.1.1.2. Chronic Paronychia
5.4.1.2. United States Paronychia Treatment Market Size and Forecast, By Treatment (2024-2032)
5.4.1.2.1. Medications
5.4.1.2.2. Surgical Interventions
5.4.1.3. United States Paronychia Treatment Market Size and Forecast, By End User (2024-2032)
5.4.1.3.1. Hospitals
5.4.1.3.2. Dermatology Clinics
5.4.1.3.3. Ambulatory Surgical Centres
5.4.2. Canada
5.4.2.1. Canada Paronychia Treatment Market Size and Forecast, By Type (2024-2032)
5.4.2.1.1. Acute Paronychia
5.4.2.1.2. Chronic Paronychia
5.4.2.2. Canada Paronychia Treatment Market Size and Forecast, By Treatment (2024-2032)
5.4.2.2.1. Medications
5.4.2.2.2. Surgical Interventions
5.4.3. Canada Paronychia Treatment Market Size and Forecast, By End User Industry (2024-2032)
5.4.3.1.1. Hospitals
5.4.3.1.2. Dermatology Clinics
5.4.3.1.3. Ambulatory Surgical Centres
5.4.4. Mexico
5.4.4.1. Mexico Paronychia Treatment Market Size and Forecast, By Type (2024-2032)
5.4.4.1.1. Acute Paronychia
5.4.4.1.2. Chronic Paronychia
5.4.4.2. Mexico Paronychia Treatment Market Size and Forecast, By Treatment (2024-2032)
5.4.4.2.1. Medications
5.4.4.2.2. Surgical Interventions
5.4.4.3. Mexico Paronychia Treatment Market Size and Forecast, By End User (2024-2032)
5.4.4.3.1. Hospitals
5.4.4.3.2. Dermatology Clinics
5.4.4.3.3. Ambulatory Surgical Centres

6. Europe Paronychia Treatment Market Size and Forecast by Segmentation (by Value in USD Million) (2024-2032)
6.1. Europe Paronychia Treatment Market Size and Forecast, By Type (2024-2032)
6.2. Europe Paronychia Treatment Market Size and Forecast, By Treatment (2024-2032)
6.3. Europe Paronychia Treatment Market Size and Forecast, By End User (2024-2032)
6.4. Europe Paronychia Treatment Market Size and Forecast, by Country (2024-2032)
6.4.1. United Kingdom
6.4.1.1. United Kingdom Paronychia Treatment Market Size and Forecast, By Type (2024-2032)
6.4.1.2. United Kingdom Paronychia Treatment Market Size and Forecast, By Treatment (2024-2032)
6.4.1.3. United Kingdom Paronychia Treatment Market Size and Forecast, By End User (2024-2032)
6.4.2. France
6.4.2.1. France Paronychia Treatment Market Size and Forecast, By Type (2024-2032)
6.4.2.2. France Paronychia Treatment Market Size and Forecast, By Treatment (2024-2032)
6.4.2.3. France Paronychia Treatment Market Size and Forecast, By End User (2024-2032)
6.4.3. Germany
6.4.3.1. Germany Paronychia Treatment Market Size and Forecast, By Type (2024-2032)
6.4.3.2. Germany Paronychia Treatment Market Size and Forecast, By Treatment (2024-2032)
6.4.3.3. Germany Paronychia Treatment Market Size and Forecast, By End User (2024-2032)
6.4.4. Italy
6.4.4.1. Italy Paronychia Treatment Market Size and Forecast, By Type (2024-2032)
6.4.4.2. Italy Paronychia Treatment Market Size and Forecast, By Treatment (2024-2032)
6.4.4.3. Italy Paronychia Treatment Market Size and Forecast, By End User (2024-2032)
6.4.5. Spain
6.4.5.1. Spain Paronychia Treatment Market Size and Forecast, By Type (2024-2032)
6.4.5.2. Spain Paronychia Treatment Market Size and Forecast, By Treatment (2024-2032)
6.4.5.3. Spain Paronychia Treatment Market Size and Forecast, By End User (2024-2032)
6.4.6. Sweden
6.4.6.1. Sweden Paronychia Treatment Market Size and Forecast, By Type (2024-2032)
6.4.6.2. Sweden Paronychia Treatment Market Size and Forecast, By Treatment (2024-2032)
6.4.6.3. Sweden Paronychia Treatment Market Size and Forecast, By End User (2024-2032)
6.4.7. Austria
6.4.7.1. Austria Paronychia Treatment Market Size and Forecast, By Type (2024-2032)
6.4.7.2. Austria Paronychia Treatment Market Size and Forecast, By Treatment (2024-2032)
6.4.7.3. Austria Paronychia Treatment Market Size and Forecast, By End User (2024-2032)
6.4.8. Rest of Europe
6.4.8.1. Rest of Europe Paronychia Treatment Market Size and Forecast, By Type (2024-2032)
6.4.8.2. Rest of Europe Paronychia Treatment Market Size and Forecast, By Treatment (2024-2032)
6.4.8.3. Rest of Europe Paronychia Treatment Market Size and Forecast, By End User (2024-2032)

7. Asia Pacific Paronychia Treatment Market Size and Forecast by Segmentation (by Value in USD Million) (2024-2032)
7.1. Asia Pacific Paronychia Treatment Market Size and Forecast, By Type (2024-2032)
7.2. Asia Pacific Paronychia Treatment Market Size and Forecast, By Treatment (2024-2032)
7.3. Asia Pacific Paronychia Treatment Market Size and Forecast, By End User (2024-2032)
7.4. Asia Pacific Paronychia Treatment Market Size and Forecast, by Country (2024-2032)
7.4.1. China
7.4.1.1. China Paronychia Treatment Market Size and Forecast, By Type (2024-2032)
7.4.1.2. China Paronychia Treatment Market Size and Forecast, By Treatment (2024-2032)
7.4.1.3. China Paronychia Treatment Market Size and Forecast, By End User (2024-2032)
7.4.2. S Korea
7.4.2.1. S Korea Paronychia Treatment Market Size and Forecast, By Type (2024-2032)
7.4.2.2. S Korea Paronychia Treatment Market Size and Forecast, By Treatment (2024-2032)
7.4.2.3. S Korea Paronychia Treatment Market Size and Forecast, By End User (2024-2032)
7.4.3. Japan
7.4.3.1. Japan Paronychia Treatment Market Size and Forecast, By Type (2024-2032)
7.4.3.2. Japan Paronychia Treatment Market Size and Forecast, By Treatment (2024-2032)
7.4.3.3. Japan Paronychia Treatment Market Size and Forecast, By End User (2024-2032)
7.4.4. India
7.4.4.1. India Paronychia Treatment Market Size and Forecast, By Type (2024-2032)
7.4.4.2. India Paronychia Treatment Market Size and Forecast, By Treatment (2024-2032)
7.4.4.3. India Paronychia Treatment Market Size and Forecast, By End User (2024-2032)
7.4.5. Australia
7.4.5.1. Australia Paronychia Treatment Market Size and Forecast, By Type (2024-2032)
7.4.5.2. Australia Paronychia Treatment Market Size and Forecast, By Treatment (2024-2032)
7.4.5.3. Australia Paronychia Treatment Market Size and Forecast, By End User (2024-2032)
7.4.6. Indonesia
7.4.6.1. Indonesia Paronychia Treatment Market Size and Forecast, By Type (2024-2032)
7.4.6.2. Indonesia Paronychia Treatment Market Size and Forecast, By Treatment (2024-2032)
7.4.6.3. Indonesia Paronychia Treatment Market Size and Forecast, By End User (2024-2032)
7.4.7. Philippines
7.4.7.1. Philippines Spatial Computing Market Size and Forecast, By Type (2025-2032)
7.4.7.2. Philippines Spatial Computing Market Size and Forecast, By Treatment (2025-2032)
7.4.7.3. Philippines Spatial Computing Market Size and Forecast, By End User (2025-2032)
7.4.8. Malaysia
7.4.8.1. Malaysia Paronychia Treatment Market Size and Forecast, By Type (2024-2032)
7.4.8.2. Malaysia Paronychia Treatment Market Size and Forecast, By Treatment (2024-2032)
7.4.8.3. Malaysia Paronychia Treatment Market Size and Forecast, By End User (2024-2032)
7.4.9. Vietnam
7.4.9.1. Vietnam Paronychia Treatment Market Size and Forecast, By Type (2024-2032)
7.4.9.2. Vietnam Paronychia Treatment Market Size and Forecast, By Treatment (2024-2032)
7.4.9.3. Vietnam Paronychia Treatment Market Size and Forecast, By End User (2024-2032)
7.4.10. Thailand
7.4.10.1. Thailand Paronychia Treatment Market Size and Forecast, By Type (2024-2032)
7.4.10.2. Thailand Paronychia Treatment Market Size and Forecast, By Treatment (2024-2032)
7.4.10.3. Thailand Paronychia Treatment Market Size and Forecast, By End User (2024-2032)
7.4.11. Rest of Asia Pacific
7.4.11.1. Rest of Asia Pacific Paronychia Treatment Market Size and Forecast, By Type (2024-2032)
7.4.11.2. Rest of Asia Pacific Paronychia Treatment Market Size and Forecast, By Treatment (2024-2032)
7.4.11.3. Rest of Asia Pacific Paronychia Treatment Market Size and Forecast, By End User (2024-2032)

8. Middle East and Africa Paronychia Treatment Market Size and Forecast by Segmentation (by Value in USD Million) (2024-2032)
8.1. Middle East and Africa Paronychia Treatment Market Size and Forecast, By Type (2024-2032)
8.2. Middle East and Africa Paronychia Treatment Market Size and Forecast, By Treatment (2024-2032)
8.3. Middle East and Africa Paronychia Treatment Market Size and Forecast, By End User (2024-2032)
8.4. Middle East and Africa Paronychia Treatment Market Size and Forecast, by Country (2024-2032)
8.4.1. South Africa
8.4.1.1. South Africa Paronychia Treatment Market Size and Forecast, By Type (2024-2032)
8.4.1.2. South Africa Paronychia Treatment Market Size and Forecast, By Treatment (2024-2032)
8.4.1.3. South Africa Paronychia Treatment Market Size and Forecast, By End User (2024-2032)
8.4.2. GCC
8.4.2.1. GCC Paronychia Treatment Market Size and Forecast, By Type (2024-2032)
8.4.2.2. GCC Paronychia Treatment Market Size and Forecast, By Treatment (2024-2032)
8.4.2.3. GCC Paronychia Treatment Market Size and Forecast, By End User (2024-2032)
8.4.3. Nigeria
8.4.3.1. Nigeria Paronychia Treatment Market Size and Forecast, By Type (2024-2032)
8.4.3.2. Nigeria Paronychia Treatment Market Size and Forecast, By Treatment (2024-2032)
8.4.3.3. Nigeria Paronychia Treatment Market Size and Forecast, By End User (2024-2032)
8.4.4. Rest of ME&A
8.4.4.1. Rest of ME&A Paronychia Treatment Market Size and Forecast, By Type (2024-2032)
8.4.4.2. Rest of ME&A Paronychia Treatment Market Size and Forecast, By Treatment (2024-2032)
8.4.4.3. Rest of ME&A Paronychia Treatment Market Size and Forecast, By End User (2024-2032)

9. South America Paronychia Treatment Market Size and Forecast by Segmentation (by Value in USD Million) (2024-2032)
9.1. South America Paronychia Treatment Market Size and Forecast, By Type (2024-2032)
9.2. South America Paronychia Treatment Market Size and Forecast, By Treatment (2024-2032)
9.3. South America Paronychia Treatment Market Size and Forecast, By End User (2024-2032)
9.4. South America Paronychia Treatment Market Size and Forecast, by Country (2024-2032)
9.4.1. Brazil
9.4.1.1. Brazil Paronychia Treatment Market Size and Forecast, By Type (2024-2032)
9.4.1.2. Brazil Paronychia Treatment Market Size and Forecast, By Treatment (2024-2032)
9.4.1.3. Brazil Paronychia Treatment Market Size and Forecast, By End User (2024-2032)
9.4.2. Argentina
9.4.2.1. Argentina Paronychia Treatment Market Size and Forecast, By Type (2024-2032)
9.4.2.2. Argentina Paronychia Treatment Market Size and Forecast, By Treatment (2024-2032)
9.4.2.3. Argentina Paronychia Treatment Market Size and Forecast, By End User (2024-2032)
9.4.3. Rest Of South America
9.4.3.1. Rest Of South America Paronychia Treatment Market Size and Forecast, By Type (2024-2032)
9.4.3.2. Rest Of South America Paronychia Treatment Market Size and Forecast, By Treatment (2024-2032)
9.4.3.3. Rest Of South America Paronychia Treatment Market Size and Forecast, By End User (2024-2032)

10. Company Profile: Key Players
10.1. Pfizer Inc. (New York, USA)
10.1.1. Company Overview
10.1.2. Business Portfolio
10.1.3. Financial Overview
10.1.4. SWOT Analysis
10.1.5. Strategic Analysis
10.1.6. Recent Developments
10.2. Novartis AG (Basel, Switzerland)
10.3. GlaxoSmithKline plc (GSK) (London, UK)
10.4. Johnson & Johnson (New Brunswick, USA)
10.5. Merck & Co., Inc. (Kenilworth, USA)
10.6. AbbVie Inc. (North Chicago, USA)
10.7. Bayer AG (Leverkusen, Germany)
10.8. Sanofi S.A. (Paris, France)
10.9. Roche Holding AG (Basel, Switzerland)
10.10. AstraZeneca plc (Cambridge, UK)
10.11. Bristol-Myers Squibb Company (New York, USA)
10.12. Eli Lilly and Company (Indianapolis, USA)
10.13. Amgen Inc. (Thousand Oaks, USA)
10.14. Teva Pharmaceutical Industries Ltd. (Tel Aviv, Israel)
10.15. Mylan N.V. (Canonsburg, USA)
10.16. Sun Pharmaceutical Industries Ltd. (Mumbai, India)
10.17. Lupin Limited (Mumbai, India)
10.18. Dr. Reddy’s Laboratories Ltd. (Hyderabad, India)
10.19. Cipla Limited (Mumbai, India)
10.20. Hikma Pharmaceuticals PLC (London, UK)
10.21. 3M Company (Saint Paul, USA)
10.22. Smith & Nephew plc (London, UK)
10.23. Medtronic plc (Dublin, Ireland)
10.24. Becton, Dickinson and Company (Franklin Lakes, USA)
10.25. Stryker Corporation (Kalamazoo, USA)
10.26. ConvaTec Group plc (Reading, UK)
10.27. Mölnlycke Health Care AB (Gothenburg, Sweden)
10.28. Coloplast A/S (Humlebaek, Denmark)
10.29. Mayo Clinic (Rochester, USA)
10.30. Cleveland Clinic (Cleveland, USA)